esc
Search documents
go
Browse entities
go
Corpus stats
go
About the data
go
AI settings
go
EFTA
Search
Search
Entities
About
Stats
Settings
⌘K
search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Modified
Date Range
Undated only
–
Email Headers
Page Count
–
Saved Searches
+
4 results for “
"Copaxone Litigation Timeline"
”
Export
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
EFTA00820341
Dataset 9
2016-08-25
6p
1,243w
Subject:
Re: Add to TEVA and AGN
From:
"Jeffrey E." <
[email protected]
>
To:
Richard Kahn
…a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year).
Copaxone Litigation Timeline
(from 2O Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist EFTA00820344 Healthcare Specialist Sales Global Equities Bank of America Merrill Lynch The power of global connections"( Find all Conference Events via the Following Link: https://gems.bankofamerica.com Disclaimer: This material was…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00820341.pdf
EFTA00820227
Dataset 9
2016-08-24
3p
568w
Subject:
Fwd: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%)
From:
Richard Kahn
To:
"jeffrey E." <
[email protected]
>
…a victory for TEVA likely sees a 1O%+ move higher in my view ($58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year).
Copaxone Litigation Timeline
(from 2Q Results Slidedeck) irrs" Scenario Analysis — BofAML Daniel Lundquist Healthcare Specialist Sales Global Equities Bank of America Merrill Lynch The power of global connections TM Find all Conference Events via the Following Link: https://gems.bankofamerica.com Disclaimer: This material…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00820227.pdf
EFTA00665656
Dataset 9
2016-08-25
6p
1,417w
Subject:
Re: Add to TEVA and AGN
From:
Richard Kahn •
To:
"Jeffrey E." <
[email protected]
>
…will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). EFTA00665659
Copaxone Litigation Timeline
(from 2Q Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist Healthcare Specialist Sales Global Equities Bank of America Merrill Lynch One Bryant Park I New York, 10036 I United States T: The power…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00665656.pdf
EFTA00820350
Dataset 9
2016-08-25
6p
1,339w
Subject:
Re: Add to TEVA and AGN
From:
"Jeffrey E." <
[email protected]
>
To:
Richard Kahn
…a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year).
Copaxone Litigation Timeline
(from 2Q Results Slidedeck) Scenario Analysis — BofAML EFTA00820353 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of global connectionsTM Find all Conference Events via the Following Link: https://gems.bankofamerica.com Disclaimer: This material was prepared by Sector Specialist Sales…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00820350.pdf
Corpus: 1990-03-17 – 2025-12-01
←
August 2016
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Undated
(150,429)
None
Light
Medium
Heavy
Results by Dataset
4 total
Set 9
4